JAGO RESEARCH AG HAS 10 DRUGS IN CLINICALS BASED ON GEOMATRIX
Executive Summary
JAGO RESEARCH AG HAS 10 DRUGS IN CLINICALS BASED ON GEOMATRIX timed- release technology. Jago, headquartered in Zollikon, Switzerland, indicated that some of the clinical trial results from the 10 drugs currently under study will be presented to FDA as part of U.S. drug approval registrations. While Jago holds the licensing rights to the Geomatrix system, the initial technology was developed by three Italian scientists at the University of Pavia, Italy. The only drug approved to date that uses the Geomatrix drug delivery system is Rhone-Poulenc Rorer's sustained-release diltiazem product Dilacor XR ("The Pink Sheet" June 15, T&G-5), which FDA approved on May 29. The Dilacor XR capsules contain a "degradable controlled- release tablet formulation" that is designed to release diltiazem over a 24-hour period. Jago said it derives some royalties from the sales. Other drug-delivery technologies in development by the Swiss firm are an aerosol inhalation therapy system that uses non- chlorofluorocarbon-containing propellants and a sustained-release gel delivery system for topical products. Jago was founded in 1983 by Jacques Conilla, PhD, the firm's president, chairman and CEO. The company has 50 employees at its Zollikon facility and a smaller division of 30 employees based in Como, Italy.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth